Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.

Oncogene 2001 Mar 1;20(9):1085-93
Vivo C, Levy F, Pilatte Y, Fleury-Feith J, Chretien P, Monnet I, Kheuang L, Jaurand MC.
INSERM E 99.09, Universite Paris Val de Marne Paris XII (EA 2345), Faculte de Medecine, 8 rue du General Sarrail, 94010, Creteil Cedex, France.

Recombinant human interferon gamma (r-hu-IFNgamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFNgamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFNgamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFNgamma. Except in the resistant cell line r-hu-IFNgamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a G2-arrest in r-hu-IFNgamma-treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFNgamma seems to depend on cyclin regulation through p21(WAF1/CIP1)- and p27(Kip1)-independent mechanisms and is not directly related to the induced DNA damage.

Source

PMID: 11314045 [PubMed - indexed for MEDLINE]
Click here to order or save article